All people with haemophilia and allied bleeding disorders receive care and treatment, wherever they live.
Haemophilia and allied bleeding disorders are treatable with proper diagnosis and care. People can lead normal lives and have a near-normal life expectancy.
Unfortunately, that’s not the case for all people with haemophilia, particularly in developing and emerging countries where many remain undiagnosed or lack adequate care.
Realising the vast disparity between standards of care around the world, Novo Nordisk, a global Danish pharmaceutical company, established the Novo Nordisk Haemophilia Foundation (NNHF) to improve care for people with haemophilia in developing and emerging countries.
NNHF reflects Novo Nordisk’s commitment to corporate social responsibility.
Apply using the step-by-step guide.
Next project application deadline: 01 September 2021
